DK1060178T3 - Heterocyklisk forbindelser som inhibitorer af rotamase enzymer - Google Patents

Heterocyklisk forbindelser som inhibitorer af rotamase enzymer

Info

Publication number
DK1060178T3
DK1060178T3 DK99901847T DK99901847T DK1060178T3 DK 1060178 T3 DK1060178 T3 DK 1060178T3 DK 99901847 T DK99901847 T DK 99901847T DK 99901847 T DK99901847 T DK 99901847T DK 1060178 T3 DK1060178 T3 DK 1060178T3
Authority
DK
Denmark
Prior art keywords
inhibitors
heterocyclic compounds
rotamase enzymes
rotamase
enzymes
Prior art date
Application number
DK99901847T
Other languages
Danish (da)
English (en)
Inventor
David Bull
Robert Maguire
Michael Palmer
Martin Wythes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK1060178T3 publication Critical patent/DK1060178T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Glass Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
DK99901847T 1998-03-02 1999-02-15 Heterocyklisk forbindelser som inhibitorer af rotamase enzymer DK1060178T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9804426.6A GB9804426D0 (en) 1998-03-02 1998-03-02 Heterocycles
PCT/IB1999/000259 WO1999045006A1 (fr) 1998-03-02 1999-02-15 Composes heterocycliques utilises en tant qu'inhibiteurs des enzymes rotamases

Publications (1)

Publication Number Publication Date
DK1060178T3 true DK1060178T3 (da) 2003-11-24

Family

ID=10827859

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99901847T DK1060178T3 (da) 1998-03-02 1999-02-15 Heterocyklisk forbindelser som inhibitorer af rotamase enzymer

Country Status (20)

Country Link
US (1) US6610707B1 (fr)
EP (1) EP1060178B1 (fr)
JP (1) JP3668133B2 (fr)
AP (1) AP9901479A0 (fr)
AR (1) AR015528A1 (fr)
AT (1) ATE248836T1 (fr)
AU (1) AU2181099A (fr)
BR (1) BR9908480A (fr)
CA (1) CA2322442A1 (fr)
CO (1) CO4790154A1 (fr)
DE (1) DE69910984T2 (fr)
DK (1) DK1060178T3 (fr)
ES (1) ES2204101T3 (fr)
GB (1) GB9804426D0 (fr)
GT (1) GT199900029A (fr)
MA (1) MA26611A1 (fr)
PA (1) PA8468501A1 (fr)
PT (1) PT1060178E (fr)
TN (1) TNSN99031A1 (fr)
WO (1) WO1999045006A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7265150B1 (en) * 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US7338976B1 (en) * 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6284779B1 (en) 1999-02-03 2001-09-04 Schering Aktiiengesellschaft Heteroaromatic compounds
IL147505A0 (en) * 1999-07-09 2002-08-14 Ortho Mcneil Pharm Inc Neurotrophic pyrrolidines and piperidines, and related compositions and methods
US6323215B1 (en) 1999-07-09 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods
WO2001004091A1 (fr) 1999-07-09 2001-01-18 Ortho-Mcneil Pharmaceutical, Inc. Derives neurotrophiques d'acide 2-azetidinecarboxylique, et compositions et methodes y relatives
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
CA2423792A1 (fr) * 2000-10-20 2002-04-25 Pfizer Products Inc. Ethanolamines alpha-aryle et utilisation de ces dernieres en tant qu'agonistes du recepteur adrenergique beta-3
TW200302717A (en) 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
US20040171614A1 (en) * 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
US7256186B2 (en) 2002-02-06 2007-08-14 Schering Corporation Gamma secretase inhibitors
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
CA2471646A1 (fr) 2002-02-27 2003-09-04 Yong Tao Procedes et intermediaires utiles dans la preparation d'agonistes du recepteur .beta.3-adrenergique
WO2003072573A1 (fr) 2002-02-27 2003-09-04 Pfizer Products Inc. Formes cristallines de (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US7144876B2 (en) * 2002-12-18 2006-12-05 Cytovia, Inc. 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
ATE417849T1 (de) 2004-04-07 2009-01-15 Pfizer Pyrazoloä4,3-düpyrimidine
EP1893569A4 (fr) * 2005-06-10 2009-08-05 Elixir Pharmaceuticals Inc Composes sulfonamide et leurs utilisations
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
NZ578391A (en) 2006-12-20 2011-02-25 Taisho Pharmaceutical Co Ltd Aryloxymethyloxadiazole derivative for the treatment of alopecia
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
TWI534142B (zh) 2011-03-15 2016-05-21 大正製藥股份有限公司 Azole derivatives
JP6020396B2 (ja) * 2012-09-12 2016-11-02 大正製薬株式会社 アゾール誘導体を含有する医薬
EP3650447A1 (fr) * 2018-11-08 2020-05-13 Universite de Nantes Nouveaux modulateurs compétitifs de récepteurs d'acétylcholine nicotinique d'insectes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55153763A (en) * 1979-05-21 1980-11-29 Kyowa Hakko Kogyo Co Ltd Modifier for citrus fruits
MX9202466A (es) * 1991-05-24 1994-06-30 Vertex Pharma Compuestos inmunosupresores novedosos.
US5859031A (en) 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
TW401408B (en) 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
US5874449A (en) * 1996-12-31 1999-02-23 Gpi Nil Holdings, Inc. N-linked sulfonamides of heterocyclic thioesters
US5721256A (en) * 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
CA2334002A1 (fr) * 1998-06-03 1999-12-09 Mark H. Norman Sulfonamides a liaison n d'acides carboxyliques n-heterocycliques ou d'isosteres d'acide carboxylique
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders

Also Published As

Publication number Publication date
US6610707B1 (en) 2003-08-26
TNSN99031A1 (fr) 2005-11-10
WO1999045006A1 (fr) 1999-09-10
MA26611A1 (fr) 2004-12-20
CA2322442A1 (fr) 1999-09-10
JP3668133B2 (ja) 2005-07-06
AP9901479A0 (en) 1999-03-31
AR015528A1 (es) 2001-05-02
DE69910984T2 (de) 2004-07-15
ES2204101T3 (es) 2004-04-16
PT1060178E (pt) 2003-12-31
EP1060178A1 (fr) 2000-12-20
CO4790154A1 (es) 1999-05-31
BR9908480A (pt) 2000-12-05
GB9804426D0 (en) 1998-04-29
JP2002505329A (ja) 2002-02-19
GT199900029A (es) 2000-08-19
EP1060178B1 (fr) 2003-09-03
AU2181099A (en) 1999-09-20
ATE248836T1 (de) 2003-09-15
PA8468501A1 (es) 2000-09-29
DE69910984D1 (de) 2003-10-09

Similar Documents

Publication Publication Date Title
DK1100797T3 (da) Heterocycliske forbindelser som inhibitorer af rotamaseenzymer
DK1060178T3 (da) Heterocyklisk forbindelser som inhibitorer af rotamase enzymer
NO960393D0 (no) Heterosykliske fenylforbindelser som COX-2-inhibitorer
NO20022649L (no) Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer
DK1077943T3 (da) Heterocykliske inhibitorer af p38
DK1001934T3 (da) Indolforbindelser som COX-2-inhibitorer
IS6289A (is) thríhringja hindrar af poly (ADP-ribosa) polymerösum
DK0951467T3 (da) Substituerede nitrogenholdige heterocykliske forbindelser som inhibitorer af p38-proteinkinase
DK1218372T3 (da) Nye heterocykliske forbindelser, der er anvendelige som reversible inhibitorer af cysteinproteaser
DK1104420T3 (da) Substituerede 1,8-naphthyridin-4(1H)-oner som phosphodiesterase-4-inhibitorer
DK1049662T3 (da) Inhibitorer af alpha4-medieret celleadhæsion
NO20022125D0 (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
DK1228073T3 (da) Imidazolforbindelser som phosphodiesterase VII-inhibitorer
DK1144425T3 (da) Derivater af monosaccharider som celleadhæsionsinhibitorer
DK1600441T3 (da) Krystallinsk form af elrcanidipinhydrochlorid til anvendelse som et antihypertensivt middel
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
DK0928291T3 (da) 3-Mercaptoacetylamino-1,5-substituerede 2-oxo-azepanderivater, der er nyttige som inhibitorer af matrixmetalloproteinase
NO20023001D0 (no) Substituerte piperazinderivater som MTP inhibitorer
NO20022123D0 (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
NO20025659L (no) Heterocykliske forbindelser
NO20005301D0 (no) Pyrrolidiner som inhibitorer av neuraminidaser
DK1147119T3 (da) 2,3-O-isopropylidenderivater af monosaccharider som celleadhæsionsinhibitorer
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer
NO20001200D0 (no) Pyrrolopyrrolonderivater som inhibitorer av neurofil elastase
DK1252327T3 (da) Fremgangsmåde til enzymatisk racematopdeling af aminomethyl-aryl-cyclohexanol-derivater